Vascular device for aneurysm treatment and providing blood flow into a perforator vessel

Abstract
A vascular device includes a body having a first, collapsed configuration and a second, expanded configuration. The body includes a plurality of heat-set strands that are braided such that when the body is in the second configuration, the strands form a plurality of pores and one or more apertures between the strands. The apertures are generally disposed at a longitudinal center region of the body. When the body is in the second configuration, the pores at proximal and distal portions of the body are generally uniform in size and smaller in size than the apertures. The pores and the apertures are substantially the same size when the body is in the first configuration.
Description
BACKGROUND

Lumens in a patient's body can change in size, shape, and/or patency, and such changes can present complications or affect associated bodily functions. For example, the walls of the vasculature, particularly arterial walls, may develop a pathological dilatation, commonly called an aneurysm. Aneurysms are observed as a ballooning-out of the wall of an artery. This is a result of the vessel wall being weakened by disease, injury, or a congenital abnormality. Aneurysms have thin, weak walls and have a tendency to rupture and are often caused or made worse by high blood pressure. Aneurysms can be found in different parts of the body; the most common being abdominal aortic aneurysms (AAA) and the brain or cerebral aneurysms. The mere presence of an aneurysm is not always life-threatening, but an aneurysm can have serious health consequences such as a stroke if one should rupture in the brain. Additionally, a ruptured aneurysm can also result in death.


SUMMARY

The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples, and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause, e.g., clause 1, 18 and 27. The other clauses can be presented in a similar manner.


1. A vascular device, comprising:

    • a body having a first, collapsed configuration and a second, expanded configuration, the body comprised of a plurality of heat-set strands;
    • wherein the strands are braided such that when the body is in the second configuration, the strands form a plurality of pores and a plurality of apertures between the strands;
    • wherein the apertures are disposed at a longitudinal center region of the body;
    • wherein, when the body is in the second configuration, the pores at proximal and distal portions of the body are generally uniform in size and smaller in size than the apertures; and
    • wherein the pores and the apertures are substantially the same size when the body is in the first configuration.


2. The vascular device of clause 1, wherein the apertures are formed by displacement of adjacent strands.


3. The vascular device of clause 1, wherein the plurality of apertures comprises two apertures.


4. The vascular device of clause 2, wherein the apertures are equally spaced and radially arranged around a longitudinal axis of the body.


5. The vascular device of clause 2, wherein a center region of each of the apertures is disposed along a single radial cross section of the body.


6. The vascular device of clause 1, wherein the plurality of apertures comprises three apertures.


7. The vascular device of clause 6, wherein the apertures are equally spaced and radially arranged around a longitudinal axis of the body.


8. The vascular device of clause 6, wherein a center region of each of the apertures is disposed along a single radial cross section of the body.


9. The vascular device of clause 1, wherein the plurality of apertures comprises four apertures.


10. The vascular device of clause 9, wherein the apertures are equally spaced and radially arranged around a longitudinal axis of the body.


11. The vascular device of clause 9, wherein a center region of each of the apertures is disposed along a single radial cross section of the body.


12. The vascular device of clause 1, wherein a number of strands in each of a proximal, center, and distal radial cross sections of the body is the same.


13. The vascular device of clause 1, wherein the body has a hoop strength that is generally uniform along the body's longitudinal length.


14. The vascular device of clause 1, wherein an area of at least one of the apertures is about 0.005 square millimeters or larger.


15. The vascular device of clause 1, wherein an area of at least one of the pores is about 0.01 square millimeters or smaller.


16. The vascular device of clause 1, wherein the apertures are larger than the pores.


17. The vascular device of clause 1, wherein a thickness of each strand is about 0.0010 to 0.0014 inches.


18. A method, for creating a plurality of apertures in a vascular device, comprising:

    • braiding a plurality of shape-memory strands to form the vascular device, wherein the strands are braided to form a plurality of pores between the strands, wherein the pores at proximal and distal portions of the device are generally uniform in size;
    • forming each of the apertures by displacing strands disposed at a longitudinal center region of the device with a tapered mandrel, wherein each aperture is larger than a pore; and
    • applying heat to the displaced strands to thereby set a shape of the displaced strands.


19. The method of clause 18, wherein the plurality of apertures comprises two apertures.


20. The method of clause 18, wherein the plurality of apertures comprises three apertures.


21. The method of clause 18, wherein the plurality of apertures comprises four apertures.


22. The method of clause 18, wherein the apertures are equally spaced and radially arranged around a longitudinal axis of the vascular device.


23. The method of clause 18, wherein a center region of each of the apertures is disposed along a single radial cross section of the vascular device.


24. The method of clause 18, wherein a number of strands in each of a proximal, center, and distal radial cross sections of the vascular device is the same.


25. The method of clause 18, wherein the vascular device has a hoop strength that is generally uniform along the device's longitudinal length.


26. The method of clause 18, wherein the apertures are larger than the pores.


27. A method for providing blood flow into a perforator vessel extending from a sac of an aneurysm, the method comprising:

    • positioning a vascular device in a vessel at an opening into the aneurysm, wherein the device has a first, collapsed configuration and a second, expanded configuration, the device comprising:
      • a plurality of heat-set strands, wherein the strands are braided such that when the device is in the second configuration, the strands form a plurality of pores and a plurality of apertures between the strands;
      • wherein the apertures are disposed at a longitudinal center region of the device;
      • wherein, when the device is in the second configuration, the pores at proximal and distal portions of the device are generally uniform in size and smaller in size than the apertures; and
      • wherein the pores and the apertures are substantially the same size when the device is in the first configuration; and
    • aligning the longitudinal center region of the device with the aneurysm to thereby provide blood flow into the perforator through one of the apertures.


28. The method of clause 27, wherein the plurality of apertures comprises two apertures.


29. The method of clause 27, wherein the plurality of apertures comprises three apertures.


30. The method of clause 27, wherein the plurality of apertures comprises four apertures.


31. The method of clause 27, wherein the apertures are equally spaced and radially arranged around a longitudinal axis of the vascular device.


32. The method of clause 27, wherein a center region of each of the apertures is disposed along a single radial cross section of the vascular device.


33. The method of clause 27, wherein a number of strands in each of a proximal, center, and distal radial cross sections of the vascular device are the same.


34. The method of clause 27, wherein the vascular device has a hoop strength that is generally uniform along the device's longitudinal length.


35. The method of clause 27, wherein the apertures are larger than the pores.


It is understood that other configurations of the subject technology will become readily apparent to those skilled in the art from the following detailed description, wherein various configurations of the subject technology are shown and described by way of illustration. As will be realized, the subject technology is capable of other and different configurations and its several details are capable of modification in various other respects, all without departing from the scope of the subject technology. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not as restrictive.





BRIEF DESCRIPTION OF THE DRAWINGS

A detailed description will be made with reference to the accompanying drawings:



FIG. 1A depicts a vascular device in a collapsed configuration, according to some embodiments of the subject technology.



FIG. 1B depicts a vascular device in an expanded configuration, according to some embodiments of the subject technology.



FIG. 1C depicts a detail view of an aperture, according to some embodiments of the subject technology.



FIG. 1D depicts a cross section taken at a longitudinal center of a vascular device, according to some embodiments of the subject technology.



FIG. 1E depicts a cross section taken at a proximal region of a vascular device, according to some embodiments of the subject technology.



FIG. 1F depicts a cross section taken at a distal region of a vascular device, according to some embodiments of the subject technology.



FIG. 2 depicts a cross section view of a vessel and delivery of a vascular device, according to some embodiments of the subject technology.



FIG. 3 depicts a cross section view of a vessel and delivery of a vascular device, according to some embodiments of the subject technology.



FIG. 4 depicts a cross section view of a vessel and delivery of a vascular device, according to some embodiments of the subject technology.



FIG. 5 depicts a cross section view of a vessel and delivery of a vascular device, according to some embodiments of the subject technology.



FIG. 6 depicts a cross section view of a vessel and deployed vascular device, according to some embodiments of the subject technology.





DETAILED DESCRIPTION

Aneurysms may be located, for example, along vessel side walls. A neck of an aneurysm typically defines an opening of between about 2 to 25 mm, though other sizes and ranges are also possible. The neck connects an anatomical vessel lumen to a fundus of the aneurysm. In some instances, “vessel” may refer to blood vessels (including arteries and veins) or other suitable body organs having a lumen, such as the gastrointestinal tract (e.g., esophagus, stomach, small intestine, colon, rectum), bile ducts, urinary bladder, ureter, urethra, trachea, bronchi, and the like. Blood flow within the anatomical lumen is channeled through the neck and into the fundus. In response to the constant blood flow into the fundus of the aneurysm, the wall of the aneurysm continues to distend and presents a significant risk of rupturing. When the blood within the aneurysm causes pressure against the wall of the aneurysm that exceeds the wall strength, the aneurysm ruptures.


Reduction of blood flow to or within the aneurysm results in a reduction in force against the wall of the aneurysm and a corresponding reduction in the risk of rupturing. Conventionally, a reduction of the force and volume of blood entering the aneurysm may be accomplished by an occluding device. The conventional occluding device restricts blood flow to the aneurysm. The aneurysm, however, may have small perforator vessels or arteries extending from the aneurysm. Because the conventional occluding device isolates the aneurysm from the blood flow in the vessel, any small perforator arteries or vessel branches (both inlet and outlet branches) extending from the aneurysm are also occluded, thereby preventing blood from flowing into the perforator vessels.


The vascular devices of the subject technology solve some or all of the foregoing problems by sufficiently restricting the blood flow into the aneurysm to prevent rupture while providing sufficient blood flow to perforator vessels or arteries extending from the aneurysm, or extending from the parent vessel sidewall near the aneurysm neck (and/or from a location on the sidewall between the proximal and distal ends of the vascular device when deployed). The vascular device includes an expandable vascular device having one or more enlarged apertures disposed near the neck of the aneurysm. The vascular device is configured to reduce the laminar flow into the aneurysm to prevent rupture, while providing sufficient blood flow to the perforator vessel through one or more of the enlarged apertures. Accordingly, the vascular device exhibits a porosity configured to reduce haemodynamic flow into the aneurysm, but simultaneously allow perfusion to perforator vessels.



FIGS. 1A-1F depict a vascular device 100, according to some embodiments of the subject technology. The vascular device 100 comprises a body 110 having a first, collapsed configuration and a second, expanded configuration. The body is comprised of a plurality of heat-set strands 112 that are braided such that when the body 110 is in the expanded configuration, the strands 112 form a plurality of pores 120 and a plurality of apertures 130 between the strands 112, as shown in FIG. 1B. When the body 110 is in the expanded configuration, the pores 120 at proximal and distal portions of the body 110 are generally uniform in size and smaller in size than the apertures 130. Referring to FIG. 1A, when the body 110 is in the collapsed configuration, the pores 120 and the apertures 130 are substantially the same size.


The body 110 may be a self-expanding stent made of two or more round or ovoid wire strands or filaments 112. In one aspect, the filaments may all be of the same thickness. For example, the thickness of each strand 112 may be about 0.0001 to 0.0020 inches. The filaments may be formed of known flexible and shape memory materials, such as nitinol. The filaments may be formed of platinum and stainless steel. The body 110 may be fabricated from platinum/8% tungsten and 35N LT (cobalt nickel alloy, which is a low titanium version of MP35N alloy) alloy wires. In other embodiments, one or more of the filaments can be formed of a biocompatible metal material or a biocompatible polymer, so long as the filaments are flexible and have shape memory properties. The filaments may be braided into a resulting lattice-like structure. In at least one embodiment, during braiding or winding of the body 110, the filaments may be loosely braided using a 1-over-2-under-2 system. In other embodiments, however, other methods of braiding may be followed, without departing from the scope of the disclosure.


The ends of the body 110 may be cut to length and therefore remain free for radial expansion and contraction. The body 110 may exhibit a high degree of flexibility due to the materials used, the porosity of the body 110, and the fact that the ends of the filaments are not secured to each other.


The pores 120 at the proximal and distal portions of the body 110 are sized to reduce haemodynamic flow into an aneurysm and the apertures 130 are sized to provide sufficient blood flow to any perforator vessels extending from the aneurysm. For example, an area of at least one of the pores 120 may be about 0.01 square millimeters or less and an area of at least one of the apertures 130 may be about 0.005 square millimeters or more. In some aspects, the apertures 130 are larger than the pores 120. In some embodiments, the apertures 130 are configured to be about five times the size of the pores 120. In some embodiments, the apertures 130 are sized to be range from about two to about ten times the size of the pores 120, while in some embodiments, the apertures 130 are sized to range from about three to about seven times the size of the pores 120.


The apertures 130 may be disposed at a longitudinal center region of the body 110 and be formed by displacement of adjacent strands, as shown in FIG. 1C. In one aspect, the vascular device 100 may have two apertures 130 disposed at the longitudinal center region of the body 110. In another example, the vascular device 100 may have three apertures 130 disposed at the longitudinal center region of the body 110. In yet another example, the vascular device 100 may have four apertures 130 disposed at the longitudinal center region of the body 110. Although FIGS. 1A-D depict four apertures 130, it is understood that a number of apertures greater than four may be suitable for many applications. The apertures 130 may be equally spaced and radially arranged around a longitudinal axis 140 of the body. In some aspects, a center region 132 of each of the apertures 130 is disposed along a single radial cross section of the body 110, as shown in FIG. 1D.


In some aspects, because the pores 120 and the apertures 130 generally comprise gaps, voids, or areas that are formed between adjacent strands 112, the number of strands 112 in each of a proximal, center, and distal radial cross sections of the body 110 is the same. For example, referring to FIGS. 1D-1F, the number of strands 112 shown at the proximal cross section of the body 110, shown in FIG. 1E, is the same as the number of strands 112 shown at the center cross section of the body 110, shown in FIG. 1D, and the distal cross section of the body 110, shown in FIG. 1F. Because the number of strands 112 at each of the proximal, center, and distal radial cross sections of the body 110 is the same, the body 110 has a hoop strength that is generally uniform along the body's 110 longitudinal length.


In one aspect, the apertures 130 may be formed on the vascular device 100 by first placing the vascular device 100 in the expanded configuration on a fixture and then inserting one or more tapered mandrels, depending on the number of apertures 130, through the body 110 to displace the strands 112 and thereby form the apertures 130. The displaced strands 112 are then heated to their shape memory temperature to “set” the displaced strands in their displaced configuration. Thereafter, the one or more mandrels are removed from the body 110 and the apertures 130 remain formed on the body 110.


When the vascular device 100 is in the collapsed configuration, the displaced strands 112 forming the apertures 130 are collapsed, along with all the strands 112 comprising the body 110, and the apertures 130 and the pores 120 are substantially the same size, as shown in FIG. 1A.


In one aspect, the vascular device may be coated with an endothelial progenitor cell coating to promote endothelium growth on an inner surface of the vascular device 100. Typically, the endothelium will grow from the proximal and/or distal ends of the vascular device 100 and traverse toward the longitudinal center of the vascular device 100. The strands 112 of the vascular device 100 serve as a substrate for the cells to attach thereto. As the inner surface of the vascular device becomes endothelialized, the pores 120 are occluded. Because the apertures 130 are larger than the pores 120, the endothelium grows around the apertures 130 but does not occlude the apertures 130. Accordingly, the apertures 130 remain unobstructed and permit blood to flow therethrough to feed any perforator vessel emanating from an aneurysm fundus, or emanating from the parent vessel sidewall near the aneurysm neck (and/or from a location on the sidewall between the proximal and distal ends of the vascular device when deployed).


Radiopaque markers may be located adjacent the proximal or distal portions of the vascular device 100, and may be located at any position along the length of the vascular device 100 between a proximal and distal end of the vascular device 100. The markers may be attached to the vascular device 100 by techniques such as adhesives, heat fusion, interference fit, fasteners, intermediate members, coatings, or by other techniques.


In some embodiments, the markers are comprised of ultrasonic markers, MRI-safe markers, or other markers. In some embodiments ultrasonic markers permit a physician to accurately determine the position of the vascular device 100 within a patient under ultrasonic visualization. Materials for an ultrasonic marker have an acoustical density sufficiently different from the vascular device 100 to provide suitable visualization via ultrasonic techniques. Exemplary materials comprise polymers, metals such as tantalum, platinum, gold, tungsten and alloys of such metals, hollow glass spheres or microspheres, and other materials.


In some embodiments, MRI-safe markers permit a physician to accurately determine the position of the vascular device 100 within a patient under magnetic resonance imaging. Exemplary materials for making MRI-safe marker have a magnetic signature sufficiently different from the vascular device 100 to provide suitable visualization via MRI techniques. Exemplary materials comprise polymers, metals such as tantalum, platinum, gold, tungsten and alloys of such metals, non-ferrous materials, and other materials.


A technique for treating an aneurysm and providing blood flow into a perforator vessel extending from a sac of the aneurysm will now be discussed with reference to FIGS. 2-5. The vascular device 100 may be delivered to a treatment site using a delivery system 200. The delivery system 200 may include a catheter, which may for example, be an over the wire (OTW) catheter, a rapid exchange (multiple lumen) catheter, or a fixed wire catheter.


Prior to delivery, an outer sheath 210 is disposed over the vascular device 100 to confine the vascular device 100 in the first, collapsed configuration. The vascular device 100 is cooperatively movable within the outer sheath 210 in order to deliver the vascular device 100 to a treatment site, such as an aneurysm 310, within the vasculature 300 of a patient.


The outer sheath 210 may be configured to be introduced and advanced through the vasculature of the patient. The outer sheath 210 may be made from various thermoplastics, e.g., PTFE, FEP, HDPE, PEEK, etc., which may optionally be lined on the inner surface of the outer sheath 140 or an adjacent surface with a hydrophilic material such as PVP or some other plastic coating. Additionally, either surface may be coated with various combinations of different materials, depending upon the desired results.


The delivery system 200 also includes a shaft 220 and a guide wire 230. The shaft 220 has a guide wire lumen for allowing the guide wire 230 to extend therethrough. The shaft 220 may also include a reduced diameter at a distal region to provide sufficient annular space in which the vascular device 100 may be stowed.


Radiopaque markers may be provided at various locations along the length of the delivery system 200. For example, an enlarged distal tip 240 of the shaft 220 may be radiopaque. In another example, radiopaque markers may be provided on the reduced diameter distal region of the shaft 220, beneath the distal and proximal end of the vascular device 100. In yet another example, a radiopaque marker 250 may be disposed on the shaft 220 adjacent to a longitudinal center of the vascular device 100, corresponding to the location of the apertures 130.


In one aspect, the vascular device 100 may be configured with differently sized apertures 130 and/or number of apertures 130. A physician may therefore select the appropriate vascular device 100 based on a size of the aneurysm and/or a number of perforators extending from the aneurysm and the diameter of each aperture 130 and/or number of apertures 130 per vascular device 100. For example, based on the diameter of each aperture 130 and the number of perforators extending from the aneurysm sac and/or from the parent vessel 300, the vascular device 100 may be selected such that the apertures 130 in fluid communication with the sac (and/or with other relevant vessel location(s)) are sufficiently large to provide sufficient blood flow to each of the perforators when the vascular device 100 is in the second, expanded configuration. The blood flow permitted by the apertures 130 to the perforators is sufficient to provide blood to downstream tissues without inducing ischemia.


In another example, based on the number of apertures 130 in the vascular device 100 and the number of perforators extending from the aneurysm sac and/or from the parent vessel 300, the vascular device 100 may be selected such that there are a sufficient number of apertures 130 in fluid communication with the sac (and/or with other relevant vessel location(s)) to provide sufficient blood flow to each of the perforators when the vascular device 100 is in the second, expanded configuration. In these applications, sufficient blood flow is provided for the perforators extending from the aneurysm sac and/or parent vessel 300 to avoid or limit ischemia to downstream tissue, but the blood flow within the aneurysm is disrupted sufficiently to permit healing of the aneurysm.


Referring to FIG. 2, the delivery system 200 is advanced percutaneously over the guide wire 230, in this example, to the site of the aneurysm 310 having a perforator vessel 320 extending therefrom.


Referring to FIG. 3, after navigating the system 200 to the treatment site within the patient, the outer sheath 210 is withdrawn proximally while maintaining the position of the shaft 220 to thereby expose a distal portion of the shaft 220 and the vascular device 100. The outer sheath 210 is withdrawn until a distal end of the outer sheath 210 is proximal of the vascular device 100. As the outer sheath 210 is withdrawn, the vascular device 100 expands. During expansion, the apertures 130 may begin to take form due to the shape memory properties of the strands 112.


Referring to FIGS. 4 and 5, the delivery system 200 may be adjusted or withdrawn proximally during deployment, until the radiopaque marker 250 and hence the apertures 130 are centered along the length of the ostium or neck of the aneurysm 310 and/or located on either side of the ostium, as appropriate. In other words, the longitudinal center region of the vascular device 100, the region having the apertures 130, is aligned with the aneurysm 310 to thereby provide blood flow into the perforator 320 through one of the apertures 130. In one aspect, the longitudinal center region of the vascular device 100 is centered along the length of the ostium so that at least one aperture 130 provides blood flow to the perforator 320 when the vascular device 110 is in the second, expanded configuration.


In one aspect, during deployment, the position of the vascular device 100 within the vessel 300 may be further modified, if after initial partial deployment of the vascular device 100, the vascular device is positioned incorrectly or otherwise has to be relocated to properly cover the treatment site. For example, the outer sheath 210 may be advanced distally, thereby encapsulating or compressing the vascular device 100 within the outer sheath 210 and allowing the system 200 to be repositioned. Accordingly, the vascular device 100 may be partially deployed, resheathed, and relocated multiple times in order to ensure that the vascular device is properly deployed in the correct location.


In another aspect, because of the woven or braided structure of the vascular device 100, the strands of the vascular device 100 can also move relative to each other, further allowing the vascular device 100 to flex and thereby permit advancement or rotation of the unexpanded portion of the vascular device 100 against an expanded portion of the vascular device 100 that is deployed within the vessel 300. Accordingly, through rotation or positioning of the unexpanded portion relative to the expanded portion of the vascular device 100, the apertures 130 of the vascular device 100 may be properly aligned and positioned at the treatment site.


Referring to FIG. 6, once the entire vascular device 100 is fully expanded, the catheter, along with the outer sheath 210, shaft 220, and guide wire 230 may be withdrawn from the patient.


Initially, blood may flow to the perforator vessel 320 from the plurality of pores 120 and apertures 130. As the inner surface of the vascular device 100 becomes endothelialized, the pores 120 will become occluded thereby preventing blood from flowing therethrough. The blood, however, will continue to flow through the apertures 130, thereby providing sufficient blood flow to the perforator 320.


In one arrangement, the vascular device 100 may be comprised of metal, polymer, ceramic, permanent enduring materials, and may comprise either or both of non-bioabsorbable and bioabsorbable materials. Exemplary materials include, but are not limited to, NITINOL®, stainless steel, cobalt chromium alloys, Elgiloy, magnesium alloys, polylactic acid, poly glycolic acid, poly ester amide (PEA), poly ester urethane (PEU), amino acid based bioanalogous polymers, tungsten, tantalum, platinum, polymers, bio-polymers, ceramics, bio-ceramics, or metallic glasses. Part or all of the medical device may elute over time substances such as drugs, biologics, gene therapies, antithrombotics, coagulants, anti-inflammatory drugs, immunomodulator drugs, anti-proliferatives, migration inhibitors, extracellular matrix modulators, healing promoters, re-endothelialization promoters, or other materials. In some embodiments, the vascular device 100 may be formed from materials having shape memory properties. In some embodiments, the vascular device 100 may be finished by processes to remove slag. In some embodiments, the vascular device 100 may be subjected to a tempering treatment at temperatures customarily applied to the material so that the impressed structure is permanently established.


The vascular device 100 may have various lengths and diameters. For example, the vascular device 100 may have specific cross-sectional diameters, the diameters being measured when the vascular device 110 is fully free to expand, ranging from about 2 mm to about 6 mm. If the vascular device 110 has a diameter between about 3 mm and about 4 mm, it may be used in a size 18 microcatheters (i.e., microcatheters with an inner diameter of approximately 0.21 inch). If the vascular device 100 has a diameter between about 5 mm and about 6 mm, it may be used in a size 27 microcatheters (i.e., microcatheters with an inner diameter of approximately 0.027 inch). However, other suitable cross-sectional diameters may be used without deviating from the scope of the subject technology. In some embodiments, the vascular device 100 may have lengths, measured proximally to distally along the longitudinal axis of the vascular device 100, ranging from about 15 mm to about 40 mm, though other ranges and sizes are also possible.


The detailed description set forth above is intended as a description of various configurations of the subject technology and is not intended to represent the only configurations in which the subject technology may be practiced. The appended drawings are incorporated herein and constitute a part of the detailed description. The detailed description includes specific details for the purpose of providing a thorough understanding of the subject technology. However, it will be apparent to those skilled in the art that the subject technology may be practiced without these specific details. In some instances, well-known structures and components are shown in block diagram form in order to avoid obscuring the concepts of the subject technology.


Skilled artisans may implement the described functionality in varying ways for each particular application. Various components and blocks may be arranged differently (for example, arranged in a different order, or partitioned in a different way) all without departing from the scope of the subject technology. It is understood that the specific order or hierarchy of steps in the processes disclosed is an illustration of exemplary approaches. Based upon design preferences, it is understood that the specific order or hierarchy of steps in the processes may be rearranged. Some of the steps may be performed simultaneously. The accompanying method claims present elements of the various steps in a sample order, and are not meant to be limited to the specific order or hierarchy presented.


The previous description is provided to enable any person skilled in the art to practice the various aspects described herein. The previous description provides various examples of the subject technology, and the subject technology is not limited to these examples. Various modifications to these aspects will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other aspects. Thus, the claims are not intended to be limited to the aspects shown herein, but is to be accorded the full scope consistent with the language claims, wherein reference to an element in the singular is not intended to mean “one and only one” unless specifically so stated, but rather “one or more.” Unless specifically stated otherwise, the term “some” refers to one or more. Pronouns in the masculine (for example, his) include the feminine and neuter gender (for example, her and its) and vice versa. Headings and subheadings, if any, are used for convenience only and do not limit the invention.


A phrase such as an “aspect” does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology. A disclosure relating to an aspect may apply to all configurations, or one or more configurations. An aspect may provide one or more examples. A phrase such as an aspect may refer to one or more aspects and vice versa. A phrase such as an “aspect” does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology. A disclosure relating to an aspect may apply to all aspects, or one or more aspects. An aspect may provide one or more examples. A phrase such as an “aspect” may refer to one or more aspects and vice versa. A phrase such as a “configuration” does not imply that such configuration is essential to the subject technology or that such configuration applies to all configurations of the subject technology. A disclosure relating to a configuration may apply to all configurations, or one or more configurations. A configuration may provide one or more examples. A phrase such as a “configuration” may refer to one or more configurations and vice versa.


The word “exemplary” is used herein to mean “serving as an example or illustration.” Any aspect or design described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other aspects or designs.


All structural and functional equivalents to the elements of the various aspects described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and are intended to be encompassed by the claims. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the claims. No claim element is to be construed under the provisions of 35 U.S.C. §112, sixth paragraph, unless the element is expressly recited using the phrase “means for” or, in the case of a method claim, the element is recited using the phrase “step for.” Furthermore, to the extent that the term “include,” “have,” or the like is used in the description or the claims, such term is intended to be inclusive in a manner similar to the term “comprise” as “comprise” is interpreted when employed as a transitional word in a claim.

Claims
  • 1. A method, comprising: positioning, at a location within a blood vessel adjacent to an aneurysm, a vascular device having a body in a first, collapsed configuration with the body comprising braided strands forming pores and apertures between the strands, and the body having a longitudinally central section; andexpanding the body from the first, collapsed configuration to a second, expanded configuration, wherein the pores are generally uniform in size and smaller in size than the apertures in the second, expanded configuration, the apertures being disposed at the longitudinally central section of the body and spaced apart from one another by the pores such that at least one of the apertures is adjacent to an ostium of the aneurysm, wherein blood flows into the aneurysm preferentially through the at least one aperture as compared to the pores.
  • 2. The method of claim 1, wherein central regions of the apertures are disposed along a single radial cross section of the body.
  • 3. The method of claim 2, wherein the body has a hoop strength that is generally uniform along a longitudinal length of the body.
  • 4. The method of claim 1, wherein the body has a hoop strength that is generally uniform along a longitudinal length of the body.
  • 5. The method of claim 1, wherein the pores and apertures are substantially the same size as each other in the first, collapsed configuration.
  • 6. The method of claim 1, wherein the expanding comprises aligning at least one of the apertures to be adjacent to an opening of a perforator vessel.
  • 7. The method of claim 1, wherein the apertures comprises four apertures.
  • 8. The method of claim 1, wherein, in the second, expanded configuration, the apertures are equally spaced and radially arranged around a longitudinal axis of the body.
  • 9. The method of claim 1, wherein, in the second, expanded configuration, an area of at least one of the apertures is 0.005 square millimeters or larger;wherein, in the second, expanded configuration, an area of at least one of the pores is 0.01 square millimeters or smaller; andwherein a thickness of each strand is 0.0010 to 0.0014 inches.
  • 10. A method, comprising: positioning, at a target location within a blood vessel, a vascular device having a body in a first, collapsed configuration with the body comprising braided strands forming pores and apertures between the strands, the pores and the apertures being substantially the same size as each other in the first, collapsed configuration; andexpanding the body from the first, collapsed configuration to a second, expanded configuration, wherein the pores have a first size and the apertures have a second size larger than the first size in the second, expanded configuration, the apertures being disposed at a longitudinally central section of the body, the pores being disposed at longitudinally proximal and distal sections of the body and between the apertures at the longitudinally central section of the body;wherein blood flows preferentially through the apertures as compared to the pores.
  • 11. The method of claim 10, wherein the expanding comprises aligning at least one of the apertures to be adjacent to an ostium of an aneurysm.
  • 12. The method of claim 10, wherein the expanding comprises aligning at least one of the apertures to be adjacent to an opening of a perforator vessel.
  • 13. The method of claim 10, wherein the apertures comprises four apertures.
  • 14. The method of claim 10, wherein, in the second, expanded configuration, the apertures are equally spaced and radially arranged around a longitudinal axis of the body.
  • 15. The method of claim 10, wherein, in the second, expanded configuration, an area of at least one of the apertures is 0.005 square millimeters or larger;wherein, in the second, expanded configuration, an area of at least one of the pores is 0.01 square millimeters or smaller; andwherein a thickness of each strand is 0.0010 to 0.0014 inches.
  • 16. A method, comprising: positioning, at a target location adjacent to an aneurysm having a perforator vessel extending therefrom, a vascular device having a body in a first, collapsed configuration with the body comprising braided strands forming pores and apertures between the strands, the apertures disposed at a longitudinally central portion of the body and separated from one another around a circumference of the body by pores; andexpanding the body from the first, collapsed configuration to a second, expanded configuration, wherein the apertures are larger than the pores in the second, expanded configuration, at least one aperture aligned with an ostium of the aneurysm such that blood flows through the aneurysm and into the perforator vessel preferentially through the at least one aperture compared to the pores.
  • 17. The method of claim 16, wherein in the first, collapsed configuration, the apertures and pores are substantially the same size as each other.
  • 18. The method of claim 16, wherein the apertures comprises four apertures.
  • 19. The method of claim 16, wherein, in the second, expanded configuration, the apertures are equally spaced and radially arranged around a longitudinal axis of the body.
  • 20. The method of claim 16, wherein, in the second, expanded configuration, an area of at least one of the apertures is 0.005 square millimeters or larger;wherein, in the second, expanded configuration, an area of at least one of the pores is 0.01 square millimeters or smaller; andwherein a thickness of each strand is 0.0010 to 0.0014 inches.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/826,147, filed Mar. 14, 2013, now U.S. Pat. No. 9,157,174, which claims priority benefit of U.S. Provisional Application Ser. No. 61/760,907, filed Feb. 5, 2013, the entirety of each of which is hereby incorporated herein by reference.

US Referenced Citations (646)
Number Name Date Kind
2919467 Mercer Jan 1960 A
4321711 Mano Mar 1982 A
4503569 Dotter Mar 1985 A
4512338 Balko et al. Apr 1985 A
4538622 Samson et al. Sep 1985 A
4572186 Gould et al. Feb 1986 A
4580568 Gianturco Apr 1986 A
4655771 Wallsten Apr 1987 A
4681110 Wiktor Jul 1987 A
4733665 Palmaz Mar 1988 A
4743251 Barra May 1988 A
4768507 Fischell et al. Sep 1988 A
4776337 Palmaz Oct 1988 A
4856516 Hillstead Aug 1989 A
4954126 Wallsten Sep 1990 A
5011488 Ginsburg Apr 1991 A
5035706 Giantureo et al. Jul 1991 A
5041126 Gianturco Aug 1991 A
5061275 Wallsten et al. Oct 1991 A
5108416 Ryan et al. Apr 1992 A
5160341 Brenneman et al. Nov 1992 A
5180368 Garrison Jan 1993 A
5192297 Hull Mar 1993 A
5197978 Hess Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5209731 Sterman et al. May 1993 A
5242399 Lau et al. Sep 1993 A
5246420 Kraus et al. Sep 1993 A
5246445 Yachia et al. Sep 1993 A
5330500 Song Jul 1994 A
5344426 Lau et al. Sep 1994 A
5360443 Barone et al. Nov 1994 A
5382259 Phelps et al. Jan 1995 A
5401257 Chevalier, Jr. et al. Mar 1995 A
5405377 Cragg Apr 1995 A
5405380 Gianotti et al. Apr 1995 A
5415637 Khosravi May 1995 A
5421826 Crocker et al. Jun 1995 A
5423849 Engelson et al. Jun 1995 A
5449372 Schmaltz et al. Sep 1995 A
5458615 Klemm et al. Oct 1995 A
5476505 Limon Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5484444 Braunschweiler Jan 1996 A
5489295 Piplani et al. Feb 1996 A
5507767 Maeda et al. Apr 1996 A
5507768 Lau et al. Apr 1996 A
5522822 Phelps et al. Jun 1996 A
5534007 St. Germain et al. Jul 1996 A
5545208 Wolff et al. Aug 1996 A
5546880 Ronyak et al. Aug 1996 A
5549662 Fordenbacher Aug 1996 A
5562641 Flomenblit et al. Oct 1996 A
5562728 Lazarus et al. Oct 1996 A
5591225 Okuda Jan 1997 A
5599291 Balbierz et al. Feb 1997 A
5601593 Freitag Feb 1997 A
5607466 Imbert et al. Mar 1997 A
5609625 Piplani et al. Mar 1997 A
5626602 Gianotti et al. May 1997 A
5628783 Quiachon et al. May 1997 A
5628788 Pinchuk May 1997 A
5632771 Boatman et al. May 1997 A
5632772 Alcime et al. May 1997 A
5636641 Fariabi Jun 1997 A
5637113 Tartaglia et al. Jun 1997 A
5639278 Dereume et al. Jun 1997 A
5645559 Hachtman et al. Jul 1997 A
D381932 Walshe et al. Aug 1997 S
5667522 Flomenblit et al. Sep 1997 A
5674276 Andersen et al. Oct 1997 A
5683451 Lenker et al. Nov 1997 A
5690120 Jacobsen Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5695499 Helgerson et al. Dec 1997 A
5700269 Pinchuk et al. Dec 1997 A
5702418 Ravenscroft Dec 1997 A
5709702 Cogita Jan 1998 A
5709703 Lukic et al. Jan 1998 A
5718159 Thompson Feb 1998 A
5725570 Heath Mar 1998 A
5733327 Igaki et al. Mar 1998 A
5735859 Fischell et al. Apr 1998 A
5741325 Chaikof et al. Apr 1998 A
5741333 Frid Apr 1998 A
5746765 Kleshinski et al. May 1998 A
5749883 Halpern May 1998 A
5749920 Quiachon et al. May 1998 A
5769884 Solovay Jun 1998 A
5769885 Quiachon et al. Jun 1998 A
5776099 Tremulis Jul 1998 A
5776142 Gunderson Jul 1998 A
5782909 Quiachon et al. Jul 1998 A
5797952 Klein Aug 1998 A
5800518 Piplani et al. Sep 1998 A
5810837 Hofmann et al. Sep 1998 A
5817102 Johnson et al. Oct 1998 A
5817105 Van Der Brug Oct 1998 A
5824039 Piplani et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824042 Lombardi et al. Oct 1998 A
5824044 Quiachon et al. Oct 1998 A
5824058 Ravenscroft et al. Oct 1998 A
5830229 Konya et al. Nov 1998 A
5833632 Jacobsen et al. Nov 1998 A
5836868 Ressemann et al. Nov 1998 A
5843168 Dang Dec 1998 A
5868754 Levine et al. Feb 1999 A
5876419 Carpenter et al. Mar 1999 A
5876445 Andersen Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5902266 Leone et al. May 1999 A
5902317 Kleshinski et al. May 1999 A
5906640 Penn et al. May 1999 A
5911717 Jacobsen et al. Jun 1999 A
5916194 Jacobsen et al. Jun 1999 A
5919204 Lukic et al. Jul 1999 A
5928260 Chin et al. Jul 1999 A
5944728 Bates Aug 1999 A
5951599 McCrory Sep 1999 A
5957973 Quiachon et al. Sep 1999 A
5957974 Thompson et al. Sep 1999 A
5964797 Ho Oct 1999 A
5980530 Willard Nov 1999 A
5980533 Holman Nov 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
6012277 Prins et al. Jan 2000 A
6014919 Jacobsen et al. Jan 2000 A
6015432 Rakos et al. Jan 2000 A
6017319 Jacobsen et al. Jan 2000 A
6019778 Wilson et al. Feb 2000 A
6019786 Thompson Feb 2000 A
6022369 Jacobsen et al. Feb 2000 A
6024754 Engelson Feb 2000 A
6024763 Lenker et al. Feb 2000 A
6027516 Kolobow et al. Feb 2000 A
6033436 Steinke et al. Mar 2000 A
6039721 Johnson Mar 2000 A
6039758 Quiachon et al. Mar 2000 A
6042589 Marianne Mar 2000 A
6051021 Frid Apr 2000 A
6056993 Leidner et al. May 2000 A
6063111 Hieshima et al. May 2000 A
6074407 Levine et al. Jun 2000 A
6077295 Limon et al. Jun 2000 A
6080191 Summers Jun 2000 A
6083257 Taylor et al. Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096052 Callister et al. Aug 2000 A
6102942 Ahari Aug 2000 A
6123712 Di Caprio et al. Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6132459 Piplani et al. Oct 2000 A
6139543 Esch et al. Oct 2000 A
6146415 Fitz Nov 2000 A
6149680 Shelso et al. Nov 2000 A
6159228 Frid et al. Dec 2000 A
6161399 Jayaraman Dec 2000 A
6165194 Denardo Dec 2000 A
6165210 Lau et al. Dec 2000 A
6165213 Goicoechea et al. Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6174330 Stinson Jan 2001 B1
6183410 Jacobsen et al. Feb 2001 B1
6183508 Stinson et al. Feb 2001 B1
6187013 Stoltze et al. Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
6197046 Piplani et al. Mar 2001 B1
6203569 Wijay Mar 2001 B1
6206868 Parodi Mar 2001 B1
6210400 Hebert et al. Apr 2001 B1
6210434 Quiachon et al. Apr 2001 B1
6210435 Piplani et al. Apr 2001 B1
6214038 Piplani et al. Apr 2001 B1
6214042 Jacobsen et al. Apr 2001 B1
6221102 Baker et al. Apr 2001 B1
6224609 Ressemann et al. May 2001 B1
6224829 Piplani et al. May 2001 B1
6231598 Berry et al. May 2001 B1
6235050 Quiachon et al. May 2001 B1
6241759 Piplani et al. Jun 2001 B1
6245087 Addis Jun 2001 B1
6245103 Stinson Jun 2001 B1
6251132 Ravenscroft et al. Jun 2001 B1
6258115 Dubrul Jul 2001 B1
6260458 Jacobsen et al. Jul 2001 B1
6261305 Marotta et al. Jul 2001 B1
6261316 Shaolian et al. Jul 2001 B1
6264671 Stack et al. Jul 2001 B1
6264689 Colgan et al. Jul 2001 B1
6270523 Herweck et al. Aug 2001 B1
6280465 Cryer Aug 2001 B1
6283991 Cox et al. Sep 2001 B1
6287331 Heath Sep 2001 B1
6287333 Appling et al. Sep 2001 B1
6290721 Heath Sep 2001 B1
6299636 Schmitt et al. Oct 2001 B1
6302810 Yokota Oct 2001 B2
6302893 Limon et al. Oct 2001 B1
6309353 Cheng et al. Oct 2001 B1
6322576 Wallace et al. Nov 2001 B1
6322586 Monroe et al. Nov 2001 B1
6322587 Quiachon et al. Nov 2001 B1
6325826 Vardi et al. Dec 2001 B1
6334871 Dor et al. Jan 2002 B1
6336938 Kavteladze et al. Jan 2002 B1
6340367 Stinson et al. Jan 2002 B1
6340368 Verbeck Jan 2002 B1
6342068 Thompson Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6348063 Yassour et al. Feb 2002 B1
6350199 Williams et al. Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6355051 Sisskind et al. Mar 2002 B1
6355061 Quiachon Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6368339 Amplatz Apr 2002 B1
6368344 Fitz Apr 2002 B1
6368557 Piplani et al. Apr 2002 B1
6375670 Greenhalgh Apr 2002 B1
6375676 Cox Apr 2002 B1
6379618 Piplani et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6389946 Frid May 2002 B1
6395017 Dwyer et al. May 2002 B1
6395021 Hart et al. May 2002 B1
6395022 Piplani et al. May 2002 B1
6398802 Yee Jun 2002 B1
6409683 Fonseca et al. Jun 2002 B1
6413235 Parodi Jul 2002 B1
6416519 VanDusseldorp Jul 2002 B1
6416536 Yee Jul 2002 B1
6419693 Fariabi Jul 2002 B1
6428489 Jacobsen et al. Aug 2002 B1
6440088 Jacobsen et al. Aug 2002 B1
6443971 Boylan et al. Sep 2002 B1
6443979 Stalker Sep 2002 B1
6454999 Farhangnia et al. Sep 2002 B1
6468301 Amplatz et al. Oct 2002 B1
6477768 Wildner Nov 2002 B1
6478778 Jacobsen et al. Nov 2002 B1
6482221 Hebert et al. Nov 2002 B1
6488705 Schmitt et al. Dec 2002 B2
6491648 Cornish et al. Dec 2002 B1
6494895 Addis Dec 2002 B2
6497711 Plaia et al. Dec 2002 B1
6503450 Afzal Jan 2003 B1
6514261 Randall et al. Feb 2003 B1
6514285 Pinchasik Feb 2003 B1
6524299 Tran et al. Feb 2003 B1
6527763 Esch et al. Mar 2003 B2
6533811 Ryan et al. Mar 2003 B1
6540778 Quiachon et al. Apr 2003 B1
6547779 Levine Apr 2003 B2
6551352 Clerc et al. Apr 2003 B2
6572646 Boylan et al. Jun 2003 B1
6576006 Limon et al. Jun 2003 B2
6582460 Cryer Jun 2003 B1
6582461 Burmeister et al. Jun 2003 B1
6589273 McDermott Jul 2003 B1
6592616 Stack et al. Jul 2003 B1
6595989 Schaer Jul 2003 B1
6602271 Adams et al. Aug 2003 B2
6602280 Chobotov Aug 2003 B2
6605110 Harrison Aug 2003 B2
6613075 Healy et al. Sep 2003 B1
6613078 Barone Sep 2003 B1
6622604 Chouinard et al. Sep 2003 B1
6623518 Thompson et al. Sep 2003 B2
6635068 Dubrul et al. Oct 2003 B1
6638243 Kupiecki Oct 2003 B2
6645240 Yee Nov 2003 B2
6646218 Campbell et al. Nov 2003 B1
6652508 Griffin Nov 2003 B2
6652574 Jayaraman Nov 2003 B1
6656212 Ravenscroft et al. Dec 2003 B2
6656218 Denardo et al. Dec 2003 B1
6660024 Flaherty Dec 2003 B1
6660032 Klumb et al. Dec 2003 B2
6663666 Quiachon et al. Dec 2003 B1
6666881 Richter et al. Dec 2003 B1
6669719 Wallace Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673100 Diaz et al. Jan 2004 B2
6679893 Tran Jan 2004 B1
6682557 Quiachon et al. Jan 2004 B1
6685735 Ahari Feb 2004 B1
6689120 Gerdts Feb 2004 B1
6689162 Thompson Feb 2004 B1
6699274 Stinson Mar 2004 B2
6702843 Brown et al. Mar 2004 B1
6709454 Cox et al. Mar 2004 B1
6712834 Yassour et al. Mar 2004 B2
6726700 Levine Apr 2004 B1
6733519 Lashinski et al. May 2004 B2
6740105 Yodfat et al. May 2004 B2
6740112 Yodfat et al. May 2004 B2
6743219 Dwyer et al. Jun 2004 B1
6755855 Yurek et al. Jun 2004 B2
6758885 Leffel et al. Jul 2004 B2
6767361 Quiachon et al. Jul 2004 B2
6773446 Dwyer et al. Aug 2004 B1
6793667 Hebert et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6814748 Baker et al. Nov 2004 B1
6818006 Douk et al. Nov 2004 B2
6833003 Jones et al. Dec 2004 B2
6849084 Rabkin et al. Feb 2005 B2
6858034 Hijlkema et al. Feb 2005 B1
6860893 Wallace et al. Mar 2005 B2
6860898 Stack et al. Mar 2005 B2
6860899 Rivelli, Jr. Mar 2005 B1
6860900 Clerc et al. Mar 2005 B2
6860901 Baker et al. Mar 2005 B1
6866677 Douk et al. Mar 2005 B2
6866679 Kusleika Mar 2005 B2
6866680 Yassour et al. Mar 2005 B2
6881221 Golds Apr 2005 B2
6887267 Dworschak et al. May 2005 B2
6890337 Feeser et al. May 2005 B2
6893451 Cano et al. May 2005 B2
6918921 Brady et al. Jul 2005 B2
6932837 Amplatz et al. Aug 2005 B2
6936055 Ken et al. Aug 2005 B1
6955685 Escamilla et al. Oct 2005 B2
6960227 Jones et al. Nov 2005 B2
6964670 Shah et al. Nov 2005 B1
6964672 Brady et al. Nov 2005 B2
6969396 Krolik et al. Nov 2005 B2
6976991 Hebert et al. Dec 2005 B2
6989024 Hebert et al. Jan 2006 B2
6994721 Israel Feb 2006 B2
7001422 Escamilla et al. Feb 2006 B2
7004962 Stinson Feb 2006 B2
7004964 Thompson et al. Feb 2006 B2
7011675 Hemerick et al. Mar 2006 B2
7037330 Rivelli, Jr. et al. May 2006 B1
7041129 Rourke et al. May 2006 B2
7066951 Chobotov Jun 2006 B2
7069835 Nishri et al. Jul 2006 B2
7074236 Rabkin et al. Jul 2006 B2
7093527 Rapaport et al. Aug 2006 B2
7101392 Heath Sep 2006 B2
7107105 Bjorklund et al. Sep 2006 B2
7118539 Vrba et al. Oct 2006 B2
7118594 Quiachon et al. Oct 2006 B2
7122050 Randall et al. Oct 2006 B2
7137990 Hebert et al. Nov 2006 B2
7166125 Baker et al. Jan 2007 B1
7169170 Widenhouse Jan 2007 B2
7169172 Levine et al. Jan 2007 B2
7172617 Colgan et al. Feb 2007 B2
7192434 Anderson et al. Mar 2007 B2
7195639 Quiachon et al. Mar 2007 B2
7195648 Jones et al. Mar 2007 B2
7201768 Diaz et al. Apr 2007 B2
7201769 Jones et al. Apr 2007 B2
7211109 Thompson May 2007 B2
7213495 McCullagh et al. May 2007 B2
7220271 Clubb et al. May 2007 B2
7235096 Van Tassel et al. Jun 2007 B1
7264632 Wright et al. Sep 2007 B2
7275471 Nishri et al. Oct 2007 B2
7279005 Stinson Oct 2007 B2
7279208 Goffena et al. Oct 2007 B1
7294137 Rivelli, Jr. et al. Nov 2007 B2
7294146 Chew et al. Nov 2007 B2
7300456 Andreas et al. Nov 2007 B2
7300460 Levine et al. Nov 2007 B2
7306624 Yodfat et al. Dec 2007 B2
7309351 Escamilla et al. Dec 2007 B2
7311031 McCullagh et al. Dec 2007 B2
7320702 Hammersmark et al. Jan 2008 B2
7323001 Clubb et al. Jan 2008 B2
7331973 Gesswein et al. Feb 2008 B2
7331976 McGuckin, Jr. et al. Feb 2008 B2
7331985 Thompson et al. Feb 2008 B2
7338518 Chobotov Mar 2008 B2
7438712 Chouinard Oct 2008 B2
7462192 Norton et al. Dec 2008 B2
7468070 Henry et al. Dec 2008 B2
7470282 Shelso Dec 2008 B2
7473271 Gunderson Jan 2009 B2
7491224 Cox et al. Feb 2009 B2
7520893 Rivelli, Jr. Apr 2009 B2
RE40816 Taylor et al. Jun 2009 E
7572288 Cox Aug 2009 B2
7572290 Yodfat et al. Aug 2009 B2
7588597 Frid Sep 2009 B2
7695507 Rivelli, Jr. et al. Apr 2010 B2
7763011 Ortiz et al. Jul 2010 B2
7771463 Ton et al. Aug 2010 B2
7854760 Molaei et al. Dec 2010 B2
7901447 Molaei et al. Mar 2011 B2
7942925 Yodfat et al. May 2011 B2
8007529 Yan Aug 2011 B2
8092486 Berrada et al. Jan 2012 B2
8092508 Leynov et al. Jan 2012 B2
8192484 Frid Jun 2012 B2
8382825 Garcia et al. Feb 2013 B2
8394119 Zaver et al. Mar 2013 B2
8398701 Berez et al. Mar 2013 B2
8617234 Garcia et al. Dec 2013 B2
8623067 Berez et al. Jan 2014 B2
8628564 Berez et al. Jan 2014 B2
8764817 Sheldon Jul 2014 B2
8801772 Shobayashi et al. Aug 2014 B2
8979918 Murayama Mar 2015 B2
9050205 Berez et al. Jun 2015 B2
9114001 Kusleika et al. Aug 2015 B2
9125659 Berez et al. Sep 2015 B2
20010027338 Greenberg Oct 2001 A1
20010044651 Steinke et al. Nov 2001 A1
20010049547 Moore Dec 2001 A1
20010056299 Thompson Dec 2001 A1
20020004667 Adams et al. Jan 2002 A1
20020007194 Plowiecki Jan 2002 A1
20020029061 Amplatz et al. Mar 2002 A1
20020035396 Heath Mar 2002 A1
20020062091 Jacobsen et al. May 2002 A1
20020078808 Jacobsen et al. Jun 2002 A1
20020082558 Samson et al. Jun 2002 A1
20020087119 Parodi Jul 2002 A1
20020111633 Stoltze et al. Aug 2002 A1
20020111648 Kusleika et al. Aug 2002 A1
20020120323 Thompson et al. Aug 2002 A1
20020138133 Lenz et al. Sep 2002 A1
20020143361 Douk et al. Oct 2002 A1
20020143384 Ozasa Oct 2002 A1
20020169473 Sepetka et al. Nov 2002 A1
20020169474 Kusleika et al. Nov 2002 A1
20020173839 Leopold et al. Nov 2002 A1
20020188314 Anderson et al. Dec 2002 A1
20020193864 Khosravi et al. Dec 2002 A1
20030009215 Mayer Jan 2003 A1
20030023299 Amplatz et al. Jan 2003 A1
20030069522 Jacobsen et al. Apr 2003 A1
20030100945 Yodfat et al. May 2003 A1
20030130684 Brady et al. Jul 2003 A1
20030135258 Andreas et al. Jul 2003 A1
20030163155 Haverkost et al. Aug 2003 A1
20030163156 Hebert et al. Aug 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030212429 Keegan et al. Nov 2003 A1
20030212430 Bose et al. Nov 2003 A1
20040024416 Yodfat et al. Feb 2004 A1
20040030265 Murayama et al. Feb 2004 A1
20040044395 Nelson Mar 2004 A1
20040073300 Chouinard et al. Apr 2004 A1
20040088037 Nachreiner et al. May 2004 A1
20040093010 Gesswein et al. May 2004 A1
20040098099 McCullagh et al. May 2004 A1
20040133223 Weber Jul 2004 A1
20040153117 Clubb et al. Aug 2004 A1
20040162606 Thompson Aug 2004 A1
20040172055 Huter et al. Sep 2004 A1
20040186368 Ramzipoor et al. Sep 2004 A1
20040193178 Nikolchev Sep 2004 A1
20040193179 Nikolchev Sep 2004 A1
20040193208 Talpade et al. Sep 2004 A1
20040199243 Yodfat Oct 2004 A1
20040210235 Deshmukh et al. Oct 2004 A1
20040215332 Frid Oct 2004 A1
20040220585 Nikolchev Nov 2004 A1
20040220608 D'Aquanni et al. Nov 2004 A1
20040220663 Rivelli Nov 2004 A1
20040254628 Nazzaro et al. Dec 2004 A1
20040260331 D'Aquanni et al. Dec 2004 A1
20050004595 Boyle et al. Jan 2005 A1
20050021075 Bonnette et al. Jan 2005 A1
20050033407 Weber et al. Feb 2005 A1
20050038447 Huffmaster Feb 2005 A1
20050051243 Forbes Jones et al. Mar 2005 A1
20050055047 Greenhalgh Mar 2005 A1
20050059889 Mayer Mar 2005 A1
20050060017 Fischell et al. Mar 2005 A1
20050090888 Hines et al. Apr 2005 A1
20050101989 Cully et al. May 2005 A1
20050137680 Ortiz et al. Jun 2005 A1
20050149111 Kanazawa et al. Jul 2005 A1
20050165441 McGuckin et al. Jul 2005 A1
20050177186 Cully et al. Aug 2005 A1
20050192620 Cully et al. Sep 2005 A1
20050197689 Molaei Sep 2005 A1
20050209672 George et al. Sep 2005 A1
20050209678 Henkes et al. Sep 2005 A1
20050246010 Alexander et al. Nov 2005 A1
20050267568 Berez et al. Dec 2005 A1
20050283220 Gobran et al. Dec 2005 A1
20050288764 Snow Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060020324 Schmid et al. Jan 2006 A1
20060036309 Hebert et al. Feb 2006 A1
20060089703 Escamilla et al. Apr 2006 A1
20060095213 Escamilla et al. May 2006 A1
20060111771 Ton et al. May 2006 A1
20060116713 Sepetka et al. Jun 2006 A1
20060116750 Hebert et al. Jun 2006 A1
20060184238 Kaufmann et al. Aug 2006 A1
20060195118 Richardson Aug 2006 A1
20060206148 Khairkhahan et al. Sep 2006 A1
20060206200 Garcia et al. Sep 2006 A1
20060206201 Garcia et al. Sep 2006 A1
20060212127 Karabey et al. Sep 2006 A1
20060271149 Berez et al. Nov 2006 A1
20060271153 Garcia et al. Nov 2006 A1
20060276910 Weber Dec 2006 A1
20070021816 Rudin Jan 2007 A1
20070043419 Nikolchev et al. Feb 2007 A1
20070055365 Greenberg et al. Mar 2007 A1
20070060994 Gobran et al. Mar 2007 A1
20070073379 Chang Mar 2007 A1
20070077347 Richter Apr 2007 A1
20070100321 Rudakov et al. May 2007 A1
20070100414 Licata May 2007 A1
20070100430 Rudakov et al. May 2007 A1
20070112415 Bartlett May 2007 A1
20070119295 McCullagh May 2007 A1
20070123969 Gianotti May 2007 A1
20070162104 Frid Jul 2007 A1
20070167980 Figulla et al. Jul 2007 A1
20070198076 Hebert et al. Aug 2007 A1
20070203559 Freudenthal et al. Aug 2007 A1
20070203563 Hebert et al. Aug 2007 A1
20070208367 Fiorella et al. Sep 2007 A1
20070208373 Zaver et al. Sep 2007 A1
20070208376 Meng Sep 2007 A1
20070208415 Grotheim et al. Sep 2007 A1
20070219619 Dieck et al. Sep 2007 A1
20070225760 Moszner et al. Sep 2007 A1
20070233175 Zaver et al. Oct 2007 A1
20070239261 Bose et al. Oct 2007 A1
20070255386 Tenne Nov 2007 A1
20070255388 Rudakov et al. Nov 2007 A1
20070280850 Carlson Dec 2007 A1
20070299500 Hebert et al. Dec 2007 A1
20070299501 Hebert et al. Dec 2007 A1
20070299502 Hebert et al. Dec 2007 A1
20080015673 Chuter Jan 2008 A1
20080033341 Grad Feb 2008 A1
20080033526 Atladottir et al. Feb 2008 A1
20080039930 Jones et al. Feb 2008 A1
20080039933 Yodfat Feb 2008 A1
20080071351 Flanagan et al. Mar 2008 A1
20080082154 Tseng et al. Apr 2008 A1
20080114391 Dieck et al. May 2008 A1
20080119943 Armstrong et al. May 2008 A1
20080125855 Henkes et al. May 2008 A1
20080208320 Tan-Malecki et al. Aug 2008 A1
20080221666 Licata et al. Sep 2008 A1
20080221670 Clerc et al. Sep 2008 A1
20080221671 Chouinard et al. Sep 2008 A1
20080255654 Hebert et al. Oct 2008 A1
20080255655 Kusleika et al. Oct 2008 A1
20080262590 Murray Oct 2008 A1
20080269774 Garcia et al. Oct 2008 A1
20080275497 Palmer et al. Nov 2008 A1
20080275498 Palmer et al. Nov 2008 A1
20080294104 Mawad Nov 2008 A1
20080300667 Hebert et al. Dec 2008 A1
20080300668 Bonsignore Dec 2008 A1
20080300673 Clerc et al. Dec 2008 A1
20090024202 Dave et al. Jan 2009 A1
20090024205 Hebert et al. Jan 2009 A1
20090030496 Kaufmann et al. Jan 2009 A1
20090030497 Metcalf et al. Jan 2009 A1
20090054981 Frid et al. Feb 2009 A1
20090099643 Hyodoh et al. Apr 2009 A1
20090105802 Henry et al. Apr 2009 A1
20090105803 Shelso Apr 2009 A1
20090125093 Hansen May 2009 A1
20090192536 Berez et al. Jul 2009 A1
20090192587 Frid Jul 2009 A1
20090198318 Berez et al. Aug 2009 A1
20090216307 Kaufmann et al. Aug 2009 A1
20090222035 Schneiderman Sep 2009 A1
20090270974 Berez et al. Oct 2009 A1
20090287241 Berez et al. Nov 2009 A1
20090287288 Berez et al. Nov 2009 A1
20090288000 McPherson Nov 2009 A1
20090292348 Berez et al. Nov 2009 A1
20090318947 Garcia et al. Dec 2009 A1
20090319017 Berez et al. Dec 2009 A1
20100010624 Berez et al. Jan 2010 A1
20100042200 Richter et al. Feb 2010 A1
20100061604 Nahm et al. Mar 2010 A1
20100063531 Rudakov et al. Mar 2010 A1
20100070024 Venturelli et al. Mar 2010 A1
20100076317 Babic et al. Mar 2010 A1
20100152834 Hannes et al. Jun 2010 A1
20100161025 Kuppurathanam et al. Jun 2010 A1
20100174269 Tompkins et al. Jul 2010 A1
20100174309 Fulkerson et al. Jul 2010 A1
20100179583 Carpenter et al. Jul 2010 A1
20100179647 Carpenter et al. Jul 2010 A1
20100198334 Yodfat et al. Aug 2010 A1
20100204779 Schuessler et al. Aug 2010 A1
20100211154 Murayama Aug 2010 A1
20100222864 Rivelli, Jr. et al. Sep 2010 A1
20100241214 Holzer et al. Sep 2010 A1
20100256732 Shin et al. Oct 2010 A1
20100256733 Schuessler Oct 2010 A1
20100280587 Ortiz et al. Nov 2010 A1
20100318174 Shaolian et al. Dec 2010 A1
20100318178 Rapaport et al. Dec 2010 A1
20110016427 Douen Jan 2011 A1
20110040372 Hansen et al. Feb 2011 A1
20110046718 Cattaneo Feb 2011 A1
20110046720 Shalev et al. Feb 2011 A1
20110054589 Bashiri et al. Mar 2011 A1
20110166592 Garcia et al. Jul 2011 A1
20110166637 Irwin et al. Jul 2011 A1
20110166639 Pulnev et al. Jul 2011 A1
20110179389 Douen Jul 2011 A1
20110184451 Sahl Jul 2011 A1
20110190862 Bashiri et al. Aug 2011 A1
20110245862 Dieck et al. Oct 2011 A1
20110270178 Fiorella et al. Nov 2011 A1
20120035643 Khairkhahan et al. Feb 2012 A1
20120041459 Fiorella et al. Feb 2012 A1
20120158124 Zaver et al. Jun 2012 A1
20120253454 Costello Oct 2012 A1
20120290067 Cam Nov 2012 A1
20120316638 Grad et al. Dec 2012 A1
20120323309 Cattaneo Dec 2012 A1
20130116773 Roeder et al. May 2013 A1
20130123901 Connor et al. May 2013 A1
20130138202 Paul et al. May 2013 A1
20130172975 Berez et al. Jul 2013 A1
20130190856 von Oepen et al. Jul 2013 A1
20130204347 Armstrong et al. Aug 2013 A1
20130211489 Makower et al. Aug 2013 A1
20130211497 Charlebois et al. Aug 2013 A1
20130274849 Zaver et al. Oct 2013 A1
20140018843 Berez et al. Jan 2014 A1
20140074149 Garcia et al. Mar 2014 A1
20140121744 Kusleika May 2014 A1
20140121746 Kusleika et al. May 2014 A1
20140128957 Losordo et al. May 2014 A1
20140222130 Kusleika Aug 2014 A1
20140316454 Zaver et al. Oct 2014 A1
20140336741 Connor et al. Nov 2014 A1
20150305748 Berez et al. Oct 2015 A1
20150313736 Berez et al. Nov 2015 A1
20150359646 Kusleika et al. Dec 2015 A1
Foreign Referenced Citations (52)
Number Date Country
101472537 Jul 2009 CN
855170 Jul 1998 EP
1683541 Jul 2006 EP
1942972 Jul 2008 EP
1872742 May 2009 EP
2 078 512 Jul 2009 EP
2556210 Apr 1988 FR
10-328216 Dec 1998 JP
11-506686 Jun 1999 JP
11-299901 Nov 1999 JP
2001-509412 Jul 2001 JP
2002-253682 Sep 2002 JP
2003-520103 Jul 2003 JP
2004-049585 Feb 2004 JP
2005-074230 Mar 2005 JP
2006-506201 Feb 2006 JP
2008-502378 Jan 2008 JP
2008-541832 Nov 2008 JP
WO-8800813 Feb 1988 WO
WO-9509586 Apr 1995 WO
WO-9532757 Dec 1995 WO
WO-9804211 Feb 1998 WO
WO-9847447 Oct 1998 WO
WO-9902092 Jan 1999 WO
WO-9905977 Feb 1999 WO
WO-9949812 Dec 1999 WO
WO-0105331 Jan 2001 WO
WO-0152771 Jul 2001 WO
WO-0205729 Jan 2002 WO
WO-0247579 Jun 2002 WO
WO-02054988 Jan 2003 WO
WO-03007840 Jan 2003 WO
WO-03043527 May 2003 WO
WO-03049600 Jun 2003 WO
WO-03057079 Jul 2003 WO
WO-03073963 Sep 2003 WO
WO-2004087006 Nov 2004 WO
WO-2005021061 Mar 2005 WO
WO-2005023149 Dec 2005 WO
WO-2006034140 Mar 2006 WO
WO-2006073745 Jul 2006 WO
WO-2006127005 Nov 2006 WO
WO-2007122396 Nov 2007 WO
WO-2008005898 Jan 2008 WO
WO-2007139689 Sep 2008 WO
WO-2007139699 Sep 2008 WO
WO-2008156683 Dec 2008 WO
WO-2005115118 Jul 2009 WO
WO-2009105710 Aug 2009 WO
WO-2010127838 Nov 2010 WO
WO-2011023105 Mar 2011 WO
WO-2011134663 Nov 2011 WO
Non-Patent Literature Citations (14)
Entry
Benndorf, et al. Treatment of a Ruptured Dissecting Vertebral Artery Aneurysm with Double Stent Placement: Case Report AJNR Am J Neuroradiol, Nov.-Dec. 2001, vol. 22, pp. 1844-1848.
Brilstra, et al., Treatment of Intracranial Aneurysms by Embolization with Coils: A Systematic Review, Stroke, Journal of the American Heart Association, 1999, vol. 30, pp. 470-476.
Ferguson, Gary, Physical Factors in the Initiation, Growth and Rupture of Human Intracranial Saccular Aneurysms, J. Neurosurg, Dec. 1972, vol. 37, pp. 666-667.
Geremia, et al., Embolization of Experimentally Created Aneurysms with Intravascular Stent Devices, ANJR American Journal of Neuroradiology, Aug. 1994, vol. 15, pp. 1223-1231.
Geremia, et al., Occlusion of Experimentally Created Fusiform Aneurysms with Porous Metallic Stents, ANJR Am J Neuroradiol, Apr. 2000, Issue 21, pp. 739-745.
Lanzino, et al., Efficacy and Current Limitations of Intravascular Stents for Intracranial Internal Carotid, Vertebral, and Basilar Artery Aneurysms, Journal of Neurosurgery, Oct. 1999, vol. 91, Issue 4, pp. 538-546.
Lieber, et al., Alteration of Hemodynamics in Aneurysm Models by Stenting: Influence of Stent Porosity, Ann of Biomedical Eng., 1997, vol. 25, pp. 460-469, Buffalo, NY.
Lieber, et al., The Physics of Endoluminal Stenting in the Treatment of Cerebrovascular Aneurysms, Neurological Research, 2002, Vcol 24, Issue Supplement 1, pp. S32-S42.
Moss, et al., Vascular Occlusion with a Balloon-Expandable Stent Occluder, Radiology, May 1994, vol. 191, Issue 2, pp. 483-486.
Pereira, Edgard, History of Endovascular Aneurysm Occlusion, Management of Cerebral Aneurysms, 2004, pp. 11-26.
Qureshi, Adnan, Endovascular Treatment of Cerebrovascular Diseases and Intracranial Neoplasms, The Lancelet, Mar. 2004, vol. 363, pp. 804-813.
Steiger, Pathophysiology of Development and Rupture of Cerebral Aneurysms, Acta Nurochirurgica, Mar 1990, vol. Supplementum 48, Pages in 62 pages.
Tenaglia, et al., Ultrasound Guide Wire-Directed Stent Deployment, Duke University Medical Center, Department of Medicine, 1993 USA.
Yu, et al., A Steady Flow Analysis on the Stented and Non-Stented Sidewall Aneurysm Models, Medical Engineering and Physics, Apr. 1999, Issue 21, pp. 133-141.
Related Publications (1)
Number Date Country
20160022451 A1 Jan 2016 US
Provisional Applications (1)
Number Date Country
61760907 Feb 2013 US
Continuations (1)
Number Date Country
Parent 13826147 Mar 2013 US
Child 14875732 US